Sep. 15 at 7:07 PM
BofA Global Research highlighted three biotech stocks with near-term catalysts.
Ascendis Pharma : Price target
$230. Key catalyst is Nov. 30 PDUFA for TransCon CNP in achondroplasia (90% success chance,
$1.1B peak sales). Skytrofa launch in Q4 and Yorvipath uptake remain central. Analysts expect Ascendis to keep first-mover advantage over MBX.
Kymera Therapeutics : Target
$54. Phase 1b data in Q4 2025 for STAT6 degrader KT-621 in atopic dermatitis, aiming to show robust activity and early clinical benefit. IRF5 degrader KT-579 expected to start Phase 1 in early 2026.
Merus : Target
$92. Expanding petosemtamab beyond HNSCC. Initial Phase 2 colorectal cancer data due H2 2025, with comparisons to current EGFR therapies. Phase 3 HNSCC trials (LiGeR-HN1, LiGeR-HN2) to finish enrollment by end-2025, with data in 2026.
$ASND $KYMR $MRUS